Shenzhen Neptunus Bioengineering Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.42%

Shenzhen Neptunus Bioengineering Co Ltd (000078) has an Asset Resilience Ratio of 0.42% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Shenzhen Neptunus Bioengineering Co Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥107.89 Million
≈ $15.79 Million USD Cash + Short-term Investments

Total Assets

CN¥25.73 Billion
≈ $3.77 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2001–2025)

This chart shows how Shenzhen Neptunus Bioengineering Co Ltd's Asset Resilience Ratio has changed over time. See Shenzhen Neptunus Bioengineering Co Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Shenzhen Neptunus Bioengineering Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 000078 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥107.89 Million 0.42%
Total Liquid Assets CN¥107.89 Million 0.42%

Asset Resilience Insights

  • Limited Liquidity: Shenzhen Neptunus Bioengineering Co Ltd maintains only 0.42% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shenzhen Neptunus Bioengineering Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shenzhen Neptunus Bioengineering Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Shenzhen Neptunus Bioengineering Co Ltd (2001–2025)

The table below shows the annual Asset Resilience Ratio data for Shenzhen Neptunus Bioengineering Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.44% CN¥116.80 Million
≈ $17.09 Million
CN¥26.33 Billion
≈ $3.85 Billion
+0.01pp
2024-12-31 0.44% CN¥125.43 Million
≈ $18.35 Million
CN¥28.80 Billion
≈ $4.21 Billion
-0.17pp
2023-12-31 0.60% CN¥194.41 Million
≈ $28.45 Million
CN¥32.30 Billion
≈ $4.73 Billion
+0.00pp
2022-12-31 0.60% CN¥217.71 Million
≈ $31.86 Million
CN¥36.25 Billion
≈ $5.30 Billion
+0.51pp
2021-12-31 0.09% CN¥35.21 Million
≈ $5.15 Million
CN¥37.60 Billion
≈ $5.50 Billion
-0.51pp
2020-12-31 0.60% CN¥239.48 Million
≈ $35.04 Million
CN¥39.72 Billion
≈ $5.81 Billion
+0.57pp
2019-12-31 0.03% CN¥13.16 Million
≈ $1.93 Million
CN¥41.17 Billion
≈ $6.02 Billion
+0.99pp
2018-12-31 -0.96% CN¥-393.95 Million
≈ $-57.65 Million
CN¥41.13 Billion
≈ $6.02 Billion
+0.23pp
2017-12-31 -1.19% CN¥-367.86 Million
≈ $-53.83 Million
CN¥30.86 Billion
≈ $4.52 Billion
+0.35pp
2016-12-31 -1.54% CN¥-256.95 Million
≈ $-37.60 Million
CN¥16.66 Billion
≈ $2.44 Billion
+0.49pp
2015-12-31 -2.03% CN¥-259.32 Million
≈ $-37.95 Million
CN¥12.76 Billion
≈ $1.87 Billion
+1.64pp
2014-12-31 -3.68% CN¥-353.99 Million
≈ $-51.80 Million
CN¥9.63 Billion
≈ $1.41 Billion
-0.52pp
2013-12-31 -3.15% CN¥-252.81 Million
≈ $-36.99 Million
CN¥8.02 Billion
≈ $1.17 Billion
-3.15pp
2012-12-31 0.00% CN¥140.92K
≈ $20.62K
CN¥5.86 Billion
≈ $858.02 Million
0.00pp
2011-12-31 0.00% CN¥132.87K
≈ $19.44K
CN¥4.84 Billion
≈ $707.56 Million
0.00pp
2010-12-31 0.00% CN¥134.46K
≈ $19.68K
CN¥4.15 Billion
≈ $606.95 Million
0.00pp
2009-12-31 0.00% CN¥125.41K
≈ $18.35K
CN¥3.16 Billion
≈ $463.10 Million
0.00pp
2008-12-31 0.00% CN¥122.23K
≈ $17.89K
CN¥2.78 Billion
≈ $406.44 Million
+0.00pp
2007-12-31 0.00% CN¥121.73K
≈ $17.81K
CN¥3.12 Billion
≈ $456.79 Million
+0.00pp
2006-12-31 0.00% CN¥100.00K
≈ $14.63K
CN¥3.52 Billion
≈ $515.44 Million
-3.71pp
2005-12-31 3.72% CN¥148.16 Million
≈ $21.68 Million
CN¥3.99 Billion
≈ $583.30 Million
-4.21pp
2004-12-31 7.92% CN¥295.35 Million
≈ $43.22 Million
CN¥3.73 Billion
≈ $545.50 Million
+7.43pp
2003-12-31 0.49% CN¥19.72 Million
≈ $2.89 Million
CN¥4.03 Billion
≈ $589.64 Million
-0.18pp
2002-12-31 0.67% CN¥23.00 Million
≈ $3.37 Million
CN¥3.43 Billion
≈ $501.82 Million
-0.44pp
2001-12-31 1.11% CN¥33.87 Million
≈ $4.96 Million
CN¥3.04 Billion
≈ $445.38 Million
--
pp = percentage points

About Shenzhen Neptunus Bioengineering Co Ltd

SHE:000078 China Drug Manufacturers - Specialty & Generic
Market Cap
$565.97 Million
CN¥3.87 Billion CNY
Market Cap Rank
#11747 Global
#3389 in China
Share Price
CN¥1.47
Change (1 day)
-5.16%
52-Week Range
CN¥1.47 - CN¥5.29
All Time High
CN¥9.81
About

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more